Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Saks Global Files for Bankruptcy Protection Amid Mounting Luxury Retail Pressures 
Rio Tinto and BHP Agree to Explore Major Iron Ore Collaboration in Pilbara 
Chevron Set to Expand Venezuela Operations as U.S. Signals Shift on Oil Sanctions 
TSMC Set to Post Record Q4 Profit as AI Chip Demand Accelerates 
U.S. Lawmakers Raise Alarm Over Trump Approval of Nvidia AI Chip Sales to China 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
Taiwan Issues Arrest Warrant for OnePlus CEO Over Alleged Illegal Recruitment Activities 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
Zhipu AI Launches GLM-Image Model Trained on Huawei Chips, Boosting China’s AI Self-Reliance Drive 
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
NEW YORK, April 06, 2017 -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of INSYS Therapeutics, Inc. (NASDAQ:INSY) who purchased shares between February 23, 2016 and March 15, 2017. The action, which was filed in the United States District Court for the Southern District of New York, alleges that the Company violated federal securities laws.
In particular, the complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose: (1) INSYS had overstated its 2015 net revenue; (2) INSYS had misstated its sales allowances for 2016; (3) accordingly, the Company lacked effective internal controls over financial reporting; and (4) as a result, INSYS' public statements were materially false and misleading at all relevant times.
Shareholders have until May 16, 2017 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-sa/insys-therapeutics-inc.
Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Joseph Klein, Esq. Empire State Building 350 Fifth Avenue 59th floor New York, NY 10118 Telephone: (212) 616-4899 Fax: (347) 558-9665 www.kleinstocklaw.com
